創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

創薬シーズ 創薬技術

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/04/24 GEM175 Elevates RPE phagocytic function to clear retinal drusen (lipoprotein deposits) and reduce oxidative stress Intermediate AMD Oral Small molecule Phase 2 ready Novel high-dose reformulation of statin previously marketed as a lipid lowering drug, now developed for the new use of treating intermediate AMD. POC clinical trial showed a marked clearance of drusen and a 75% reduction in progression to late AMD (CNV/GA). Abbreviated 505(b)(2) pathway. Patent applications have been made globally. 問合せ
20/04/24 GEM174 Invadopodia-Targeted siRNA Advanced and/or highly metastatic cancers* i.v. Nucleic acid Pre-IND Invadopodia mediates cancer cell invasion, intravasation and extravasation.
Master Invadopodial Regulators (MIRs) are the driver genes of cancer invasiveness and metastasis and are rarely expressed by normal cells.
MIR-1 is also a cardinal regulator of Wnt activity and tumor growth. GEM174 is a lipid nanoparticles-formulated siRNA specifically targeting MIR-1. GEM174 suppressed many tumor growth and extended survival time in xenograft model.
*hepatocellular carcinoma, triple-negative breast cancer, and gastric adenocarcinoma 		問合せ
20/04/22 GEM173 Anti-fibrotic effects Anti-Fibrotic-Treatment of patients after Aortic-Valve-Implantation Oral Small molecule Phase 1 Combibnation of marketed small molecure drugs to exert anti-fibrotic effects. A novel anti-fibrotic therapy is supposed to reduce progression of fibrosis and stabilize heart functioning. Myocardial fibrosis was found to independently predict cardiovascular mortality after AVI. Patent application has been made globally.
Discussions are available for Japanese companies and Chinese companies. 		問合せ
20/04/22 GEM172 Activation of multiple sulfatase Multiple Sulfatase Deficiency Oral / or injection Small molecule Preclinical – Phase 1 study in preparation No effective treatment for the rare disease MSD is available. Combination of marketed drugs increase the activity of multiple sulfatases and significantly reduce toxic glycosaminoglycans in MSD fibroblast cell lines. Priority patent, which lead to global application, has been filed.
Discussions are available for Japanese companies and Chinese companies. 		問合せ
20/04/22 GEM171 ARNT regulation Fibrosis in kidney, heart and liver Oral / or gene therapy Small molecule or morpholinos Discovery – Preclinical No effective therapy for fibrosis is available yet. ARNT homodimerizartion attenuates fibrosis progression and induces regenerative cellular responses. Several mechanisms of action and potential drugs were identified, which show inhibition of ARNT degradation or activation of ARNT expression. PCT pattent application filed.
Discussions are available for Japanese companies and Chinese companies. 		問合せ
20/04/22 GEM170 Improved PCR Diagnostic for detection of Para- tuberculosis in animals and potentially Crohn's disease in humans in vitro Others POC obtained in animals New and improved PCR diagnostic test for fast and early detection of Mycobacterium avium subspecies paratuberculosis (MAP). This method shows better performance than current ELISA as well as on current PCR tests. Diagnostic test for early MAP detection in domestic livestocks, exotic ruminations and human patients.
Discussions are available for Japanese companies and Chinese companies.
* Successfully tested in feces, blood, milk, sperm and tissue samples 		問合せ
20/04/16 GEM-CVD02 Immune modulation (reduction of cytokine storm) with anti-viral medicine COVID-19 Oral Small molecule Launch COVID-19 progressing process is by first infecting from the virus and intriguing immune system modulated pro-inflammation, further proceeding to more serious inflammation, and later evolving to commencement of pro-fibrosis with infected pneumonia.TLR4 signaling pathway is closely associated with inflammation, immunity, and lung diseases. A TLR4 antagonist works well as an immune modulator for applications on pro-inflammatory diseases. GEM-CVD02 is a launched compound that has TLR4 antagonist activity and is expected the efficasy in combination of anti-viral medicine. GMP manufactured and FDA approved CTM capsules of this candidate are ready for clinical trial uses. 問合せ
20/04/10 GEM-CVD01 SARS-CoV-2 spike protein expression from RNA followed by antibody response COVID-19 Intra- muscular RNA Vaccine Preclinical This program is a rapid COVID-19 vaccine development. This vaccine is developed on the basis of established technologies of RNA delivery and nanostructured lipid carrier formulation. GEM-CVD01 rapidly induces robust immune responses. 問合せ
20/04/10 GEM169 Novel mechanism of action in anti-viral drug Herpes zoster*, Genital Herpes** and Herpes Labialis** Oral Small molecule Launch*, Phase 3** GEM169 is a herpes viral enzyme inhibitor, that exhibits higher in vitro antiviral activity against both VZV and HSV than existing nucleic acid analogs.
-Once daily dosing to support adherence
-No cross-resistance with existing nucleic acid analogs
-Low emergence of GEM169-resistant virus strains
-No major safety concerns to date
-No need to adjust dosage for renal-impaired patients (Hepatic excretion type drug) 		問合せ
20/04/10 GEM168 Heat-killed mycobacterium vaccae Tuberculosis （TB） Oral Vaccine Phase 3 First-in-class tuberculosis immunotherapy to be used as an oral adjunct to standard TB drugs. In a 1-month phase 2 trial, the mycobacterial clearance in sputum smears was observed in 72% and 19% of patients on GEM168 and placebo, respectively. 問合せ